Biogen Buys Apellis for $5.6B to Expand Kidney DrugsBloomberg1 Apr 2026Duration: 1:46Read the full storyUp nextFortress's Burton: Investors More Discerning on AIGTA VI Becomes Best-Reviewed Video Game EverNvidia Earnings Impress, But Succession Risk LingersAnthropic's VC Backers Double Down Ahead of IPOAnthropic IPO Demand Sets Stage for Historic DebutCredit Chiefs Warn of 'Fear Factor' With Debt Repricing